$35.07▲ 1.46 (4.34%)
Real-time prices · US MarketsClean balance sheet with low leverage (0.0× debt-to-equity).
low return on equity (-65%).
Quality
1.6
Health
8.7
Growth
5.1
Valuation
5.7
Sentiment
7.1
Analyst Target
$45.76
▲ +30.5% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-14.4×
next 12 months est.
Market Cap
$7.2B
market capitalization
Div Yield
—
dividend yield
Profit Margin
0.0%
net profit margin
Gross Margin
0.0%
revenue minus COGS
ROE
-64.8%
return on equity
Beta
0.79
vs S&P 500
52-Week Range
$14 — $36
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Immunovant, Inc. right now?
Immunovant, Inc.'s Q·Score is 5.4/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.0× debt-to-equity). Key area to monitor: low return on equity (-65%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for IMVT?
The consensus price target for IMVT is $45.76, based on ratings from 17 Wall Street analysts. This is 30.5% above the current price of $35.07. Price targets are forward-looking estimates and not guarantees of future performance.
Is IMVT overvalued or undervalued?
Immunovant, Inc. (IMVT) scores in line with sector averages on valuation metrics. The consensus analyst price target of $45.76 is 30% above the current price.
When does Immunovant, Inc. report its next earnings?
Immunovant, Inc.'s next earnings report is expected on approximately August 10, 2026.
What is Immunovant, Inc.'s profit margin?
Immunovant, Inc. has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.
How much debt does Immunovant, Inc. have?
Immunovant, Inc. has a debt-to-equity ratio of 0.00×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 9.09×, indicating comfortable short-term liquidity.